521 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Acquired by Crew Capital Management Ltd.

Crew Capital Management Ltd. bought a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the fourth quarter, HoldingsChannel.com reports. The firm bought 521 shares of the pharmaceutical company’s stock, valued at approximately $212,000.

A number of other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in Vertex Pharmaceuticals by 0.4% during the third quarter. Vanguard Group Inc. now owns 21,983,356 shares of the pharmaceutical company’s stock worth $7,644,492,000 after acquiring an additional 87,397 shares during the last quarter. Jennison Associates LLC boosted its position in Vertex Pharmaceuticals by 3.9% during the fourth quarter. Jennison Associates LLC now owns 3,944,913 shares of the pharmaceutical company’s stock worth $1,605,146,000 after acquiring an additional 147,248 shares during the last quarter. Morgan Stanley boosted its position in Vertex Pharmaceuticals by 3.2% during the third quarter. Morgan Stanley now owns 2,870,101 shares of the pharmaceutical company’s stock worth $998,050,000 after acquiring an additional 89,217 shares during the last quarter. Northern Trust Corp boosted its position in Vertex Pharmaceuticals by 4.9% during the third quarter. Northern Trust Corp now owns 2,813,563 shares of the pharmaceutical company’s stock worth $978,388,000 after acquiring an additional 131,539 shares during the last quarter. Finally, Invesco Ltd. boosted its position in Vertex Pharmaceuticals by 3.5% during the third quarter. Invesco Ltd. now owns 2,016,780 shares of the pharmaceutical company’s stock worth $701,315,000 after acquiring an additional 67,451 shares during the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. HC Wainwright lifted their price target on shares of Vertex Pharmaceuticals from $457.00 to $462.00 and gave the company a “buy” rating in a report on Thursday, April 11th. Wells Fargo & Company lifted their price target on shares of Vertex Pharmaceuticals from $500.00 to $540.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Sanford C. Bernstein lowered shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Friday, February 2nd. Wolfe Research started coverage on shares of Vertex Pharmaceuticals in a report on Thursday, February 15th. They issued an “outperform” rating and a $515.00 price target on the stock. Finally, William Blair restated an “outperform” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, February 6th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $429.45.

Vertex Pharmaceuticals Trading Down 0.3 %

Shares of VRTX stock traded down $1.28 during trading hours on Monday, reaching $396.20. 604,508 shares of the stock traded hands, compared to its average volume of 1,220,388. Vertex Pharmaceuticals Incorporated has a 1-year low of $320.01 and a 1-year high of $448.40. The business has a fifty day moving average price of $411.60 and a 200 day moving average price of $399.17. The company has a quick ratio of 3.78, a current ratio of 3.99 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $102.40 billion, a PE ratio of 28.62, a PEG ratio of 1.87 and a beta of 0.35.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.85 by $0.35. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. The business had revenue of $2.52 billion for the quarter, compared to analyst estimates of $2.50 billion. During the same quarter in the previous year, the business earned $3.33 earnings per share. On average, equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 14.95 EPS for the current year.

Insider Activity

In other news, COO Stuart A. Arbuckle sold 4,295 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $420.24, for a total transaction of $1,804,930.80. Following the sale, the chief operating officer now owns 75,718 shares in the company, valued at $31,819,732.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Vertex Pharmaceuticals news, COO Stuart A. Arbuckle sold 4,295 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $1,804,930.80. Following the completion of the sale, the chief operating officer now directly owns 75,718 shares of the company’s stock, valued at $31,819,732.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Ourania Tatsis sold 480 shares of the company’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $420.79, for a total transaction of $201,979.20. Following the sale, the executive vice president now directly owns 59,827 shares of the company’s stock, valued at $25,174,603.33. The disclosure for this sale can be found here. Insiders have sold 12,381 shares of company stock worth $5,203,249 over the last 90 days. 0.20% of the stock is owned by company insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.